

Table S2: PFU/ml obtained with the treatment with di-halogenated compounds derived from L-Tyrosine in combined strategy.

	DENV-2/S16803	ZIKV/Col	CHIKV/Col
<i>Control</i>	1.25x10 ⁰⁶	1.71x10 ⁰⁶	3.35x10 ¹⁷
<i>Suramine</i>	<1.00x10 ⁰⁰	<1.00x10 ⁰⁰	<1.00x10 ⁰⁰
<i>Ribavirin</i>	6.25x10 ⁰⁴	9.80x10 ⁰⁴	2.63x10 ¹⁶
<i>TDC</i>	7.69x10 ⁰⁶	4.63x10 ⁰⁶	1.49x10 ¹⁷
<i>TDB</i>	6.00x10 ⁰⁶	4.44x10 ⁰⁶	1.13x10 ¹⁷
<i>TDC_2M_ME</i>	3.25x10 ⁰⁶	5.85x10 ⁰⁵	7.63x10 ¹⁶
<i>TDB_2M_ME</i>	2.94x10 ⁰⁶	9.27x10 ⁰⁵	5.06x10 ¹⁶
<i>TDC_2M</i>	3.50x10 ⁰⁶	4.50x10 ⁰⁶	9.56x10 ¹⁶
<i>TDB_2M</i>	1.83x10 ⁰⁶	4.69x10 ⁰⁶	1.16x10 ¹⁷
<i>TDC_3M_ME</i>	3.56x10 ⁰⁶	4.06x10 ⁰⁶	1.26x10 ¹⁷
<i>TDB_3M_ME</i>	6.31x10 ⁰⁶	7.44x10 ⁰⁶	1.70x10 ¹⁷
<i>TDC_3M</i>	5.19x10 ⁰⁶	8.13x10 ⁰⁶	1.46x10 ¹⁷
<i>TDB_3M</i>	3.69x10 ⁰⁶	3.94x10 ⁰⁶	1.34x10 ¹⁷